"Immunogenicity, Vaccine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The capacity of VACCINES to stimulate the ADAPTIVE IMMUNE RESPONSE to produce antibodies and antigen-specific T-CELL responses.
| Descriptor ID |
D000071497
|
| MeSH Number(s) |
G12.070.500 G12.450.050.370.500 G12.450.050.460 G12.513
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunogenicity, Vaccine".
Below are MeSH descriptors whose meaning is more specific than "Immunogenicity, Vaccine".
This graph shows the total number of publications written about "Immunogenicity, Vaccine" by people in this website by year, and whether "Immunogenicity, Vaccine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 3 | 1 | 4 |
| 2017 | 0 | 3 | 3 |
| 2018 | 2 | 2 | 4 |
| 2019 | 4 | 6 | 10 |
| 2020 | 1 | 4 | 5 |
| 2021 | 2 | 4 | 6 |
| 2022 | 2 | 4 | 6 |
| 2023 | 1 | 6 | 7 |
| 2024 | 2 | 5 | 7 |
| 2025 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunogenicity, Vaccine" by people in Profiles.
-
Immunogenicity and Reactogenicity of High- or Standard-Dose Influenza Vaccine in a Second Consecutive Influenza Season. J Infect Dis. 2025 Feb 04; 231(1):e123-e131.
-
Immunogenicity of COVID-19 Vaccines During Pregnancy: A Systematic Review and Comparison of Pregnant Versus Nonpregnant Persons. Pediatr Infect Dis J. 2025 Feb 01; 44(2S):S27-S31.
-
Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59?. Vaccine. 2025 Feb 15; 47:126702.
-
Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization. Front Immunol. 2024; 15:1480976.
-
Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases. Nat Commun. 2024 Aug 29; 15(1):7469.
-
Bivalent Omicron BA.4/BA.5 BNT162b2 Vaccine in 6-Month- to <12-Year-Olds. J Pediatric Infect Dis Soc. 2024 Aug 24; 13(8):421-429.
-
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clin Infect Dis. 2024 Jun 14; 78(6):1757-1768.
-
Immunophenotypic predictors of influenza vaccine immunogenicity in pediatric hematopoietic cell transplant recipients. Blood Adv. 2024 04 23; 8(8):1880-1892.
-
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial. Lancet Infect Dis. 2024 Jul; 24(7):760-774.
-
Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial. J Infect Dis. 2024 Feb 14; 229(2):327-340.